Anzeige
Mehr »
Montag, 03.11.2025 - Börsentäglich über 12.000 News
Der menschliche Genius hinter den Maschinen: Telescope Innovations und der Aufstieg der autonomen Wissenschaft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DQF9 | ISIN: US36870H1032 | Ticker-Symbol:
NASDAQ
31.10.25 | 20:56
8,050 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENELUX CORPORATION Chart 1 Jahr
5-Tage-Chart
GENELUX CORPORATION 5-Tage-Chart

Aktueller Chart GENELUX Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
GENELUX CORPORATION-Investoren interessieren sich auch für diese Wertpapiere
InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementJENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")...
► Artikel lesen
InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business UpdateINF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals...
► Artikel lesen
InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
► Artikel lesen
Atossa Therapeutics Inc: Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial...
► Artikel lesen
Atossa Therapeutics Inc: Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling ActivitiesChanges are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans SEATTLE, Oct. 6, 2025 /PRNewswire/...
► Artikel lesen
RedChip Companies, Inc.: NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVORLANDO, FL / ACCESS Newswire / August 29, 2025 / RedChip Companies will air interviews with NioCorp Developments Ltd. (Nasdaq:NB) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks...
► Artikel lesen
RedHill Biopharma Receives Nasdaq Staff Determination NotificationOn October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum...
► Artikel lesen
RedHill Biopharma Ltd.: RedHill's Talicia Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealCumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S....
► Artikel lesen
RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2025 Financial Results and Operational HighlightsExtensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: ...
► Artikel lesen